Camrelizumab

Generic Name: Camrelizumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1798286-48-2

Unique Ingredient Identifier: 73096E137E

Background: Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Indication: ⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。

⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。

⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。

⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Phase 2

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: SHR-1210

First Posted Date: 2021-03-10

Last Posted Date: 2021-03-10

Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Target Recruit Count: 71

Registration Number: NCT04790539

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Phase 2

Recruiting

Conditions: Metastatic Gastroesophageal Junction Adenocarcinoma
Metastatic Gastric Adenocarcinoma

Interventions: Drug: Camrelizumab
Drug: Apatinib Mesylate
Drug: S1
Drug: Docetaxel injection

First Posted Date: 2021-03-04

Last Posted Date: 2021-05-17

Lead Sponsor: Zhou Fuxiang

Target Recruit Count: 35

Registration Number: NCT04781686

Locations: 🇨🇳
Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Conditions: Advanced Colorectal Carcinoma

First Posted Date: 2021-02-25

Last Posted Date: 2021-02-25

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT04771715

Locations: 🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Camrelizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Albumin paclitaxel

First Posted Date: 2021-02-24

Last Posted Date: 2021-02-24

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 200

Registration Number: NCT04768075

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Not Applicable

Conditions: Esophageal Squamous Cell Carcinomas

Interventions: Drug: Camrelizumab
Radiation: radiotherapy

First Posted Date: 2021-02-05

Last Posted Date: 2021-02-05

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 20

Registration Number: NCT04741490

Locations: 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Phase 2

Completed

Conditions: Biliary Tract Cancer
Anti-PD-1 Therapy
Targeted Molecular Therapy
Capecitabine

Interventions: Drug: Camrelizumab
Drug: apatinib
Drug: Capecitabine

First Posted Date: 2021-01-22

Last Posted Date: 2024-01-30

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 28

Registration Number: NCT04720131

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Phase 1

Active, not recruiting

Conditions: Urinary Bladder Neoplasms
Immunotherapy

Interventions: Drug: Camrelizumab

First Posted Date: 2021-01-13

Last Posted Date: 2024-07-12

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04706598

Locations: 🇨🇳
Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine, Shanghai, Shanghai, China

and more 1 locations

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Camrelizumab
Drug: S-1
Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2021-01-05

Last Posted Date: 2024-02-07

Lead Sponsor: Quan Wang

Target Recruit Count: 37

Registration Number: NCT04694183

Locations: 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Phase 2

Conditions: Small-cell Lung Cancer

Interventions: Drug: camrelizumab
Drug: Apatinib Mesylate
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2020-12-24

Last Posted Date: 2020-12-24

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 69

Registration Number: NCT04683198

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent or Metastatic Cervical Cancer

Interventions: Drug: SHR-1210
Drug: Physician's choice chemotherapy
Drug: SHR-1020

First Posted Date: 2020-12-23

Last Posted Date: 2022-11-15

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 194

Registration Number: NCT04680988

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy